Clostridium difficile infection resident survival guide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2], Rim Halaby, M.D. [3]

Synonyms and keywords: CDI

Definition

Clostridium difficile infection (CDI) is defined as the acute onset of diarrhea (≥ 3 unformed stools in ≤24 hours) with either documented toxigenic Clostridium difficile (C. difficile) or its toxin, or colonoscopic or histopathological findings of pseudomembranous colitis in the absence of any other documented cause of diarrhea.

• Health-care facility onset health-care facility associated (HO-HCFA): Onset of symptoms within 3 days of admission to a health-care facility
• Community onset health-care facility associated (CO-HCFA): Onset of symptoms within 4 weeks of discharge from a health-care facility
• Community onset (CA): Onset of symptoms outside health-care facility or <3 days after admission to a health-care facility and has not been discharged from health-care facility in the previous 12 weeks
• Indeterminate or unknown: Onset of symptoms after being discharged from a health-care facility 4-12 weeks previously

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Clostridium difficile infection itself may present or complicate as a life-threatening condition and must be treated as such irrespective of the causes.

Common Causes

• Cephalosporins
• Clindamycin
• Fluoroquinolones
• Histamine 2 receptor antagonists
• Penicillins
• Proton-pump inhibitors (PPIs)

Management

Characterize the symptoms: ❑ Diarrhea (Onset, duration, pattern, bloody or watery) ❑ Mental status change ❑ Fever ❑ Abdominal pain ❑ Abdominal distention ❑ Nausea ❑ Vomiting ❑ Loss of appetite

Examine the patient: 1. Assess volume status: ❑ General condition ❑ Thirst ❑ Pulse ❑ Blood pressure ❑ Eyes ❑ Mucosa 2. General examination: ❑ Extremities (edema) ❑ Abdomen (Distension or tenderness) ❑ Anorectal (Bleeding) ❑ CVS ❑ RS

Order tests: ❑ CBC ❑ ESR ❑ Serum electrolytes ❑ Total serum protein and albumin ❑ Stool analysis ❑ Urinalysis ❑ BUN ❑ Creatinine ❑ Serum glucose

Order tests for C. difficile ❑ Nucleic acid amplification tests (NAAT) for C. difficile toxin genes such as PCR (Standard), OR ❑ Two or three steps glutamate dehydrogenase (GDH) screening with subsequent toxin A and B enzyme immunoassay

❑ Discontinue any inciting antibiotics ❑ Take infection control precaution: ♦ Place the patient in a private room or in a room with another patient when CDI is suspected or confirmed ♦ Use and hygiene and barrier precautions ♦ Use single use disposable equipement ♦ Disinfect environmental surfaces ❑ Assess the severity of the patient's condition to tailor the management

Mild or moderate initial episode ❑ Diarrhea plus any additional signs or symptoms not meeting severe or complicated criteria

Severe initial episode ❑Serum albumin <3g/dl Plus: Any ONE of the following: ❑ WBC ≥15,000 cells/mm3 ❑ Abdominal tenderness

Complicated severe initial episode ❑ Admission to the intensive care unit for CDI ❑ Hypotension with or without required use of vasopressors ❑ Fever ≥38.5 °C ❑ Ileus or significant abdominal distention ❑ Mental status changes ❑ Serum lactate levels >2.2 mmol/l ❑ WBC ≥35,000 cells/mm3 or <2,000 cells/mm3 ❑ End organ failure (mechanical ventilation, renal failure, etc.)

❑ Deliver supportive care ♦ IV fluid resuscitation ♦ Electrolyte replacement ♦ VTE prophylaxis ❑ Order a CT scan ❑ Obtain a surgical consult

❑ Administer antibiotics: Metronidazole 500 mg 3 times/day, orally, for 10 days

❑ Administer antibiotics: Vancomycin 125 mg 4 times/day for 10 days

Absence of abdominal distention: ❑ Administer antibiotics: ♦ Vancomycin 125 mg 4 times/day, orally or by NG tube, PLUS ❑♦ Metronidazole 500 mg 3 times/day ❑ Continue oral or enteral feeding

Presence of significant abdominal distention: ❑ Administer antibiotics: ♦ Vancomycin 500 mg 4 times/day, orally or by NG tube, PLUS ♦ Vancomycin 500 mg in a volume of 500 mL, per rectum, 4 times/day, PLUS ♦ IV Metronidazole 500 mg 3 times/day

First recurrence? ❑ Repeat the treatment of the initial episode ❑ Use vancomycin if severe

Second recurrence? ❑ Administer vancomycin in a tapered and/or pulsed way

Third recurrence? ❑ Consider fecal microbiota transplant (FMT)

The algoithm is based on the 2013 American Journal of Gastroenterology guidelines.

Do's

• Only unformed stools from patients with diarrhea should be tested for C. difficile. Inform the laboratory when a patient with ileus and complicated disease has a formed stool.

• Rectal swabs can be used for PCR and thus may be useful in timely diagnosis of patients with ileus.

• Add vancomycin therapy delivered via enema to treatments in patients in whom oral antibiotics cannot reach a segment of the colon, such as with Hartman’s pouch, ileostomy, or colon diversion.

• Test for C. difficile among patients with diarrhea in the context of immunosuppression, such as malignancy, chemotherapy, corticosteroid therapy, organ transplantation, and cirrhosis.

• Test for C. difficile among pregnant or periparturient women with diarrhea because of the increased rate of maternal and fetal mortality.

Management of CDI in IBD Patients

• Test for C. difficile among all patients with IBD who develop diarrhea following recent hospitalization or antibiotic use or in the setting of previously quiescent disease or with a disease flare.
• Test for C. difficile among all patients with an IBD flare.
• Consider the simultaneous treatment for IBD flare and empiric therapy against CDI among IBD patients who have severe colitis.

Don't s

• Don't screen for clostridium difficle among patients without diarrhea.
• Don't repeat testing for negative tests.
• Dont use anti-peristaltic agents to control diarrhea for confirmed or suspected CDI patients, as they may obscure symptoms and precipitate complicated disease.
• Repeat testing should be discouraged as it increases the likelihood of false positives and if requested, the physician should confer with the laboratory to explain the clinical rationale.
• Empiric therapy for CDI should not be discontinued or withheld in patients with a high pre-test suspicion for CDI.
• Dont treat asymptomatic C.Difficle carriers as treating such patients may increase the shedding of spores and growth of new resistant strains.
• Don't test for cure following an episode of clostridium difficile diarrhea.
• The evidence for the use of probiotics, Lactobacillus casei, Lactobacillus bulgaricus, and Streptococcus thermophilus to decrease the incidence of antibiotic-associated diarrhea is insufficient.

References

Template:WikiDoc Sources